NNovo Nordisk Read More Novo Nordisk Bets on Oral Access and Combination Research to Revive Growth Story2026-06-05 Novo Nordisk launches oral Wegovy in UAE (first outside US) and tests combination with Veru for older adults.…
NNovo Nordisk Read More Novo Nordisk Bets on Buybacks and Pipeline Data as Prescription Boom Meets Washington Pricing Pressu2026-06-02 Novo Nordisk’s oral obesity therapy drives 2M prescriptions in 5 months, but shares tumble 48% from peak amid…
NNovo Nordisk Read More Novo Nordisk Bets on CagriSema and Oral Wegovy to Counter Pricing Headwinds and Analysts’ Caution2026-05-31 Novo Nordisk faces key test at ADA with CagriSema Phase 3 data; Wegovy oral prescriptions surge, European reimbursement…
NNovo Nordisk Read More Novo Nordisk Bets on Oral Pill and CagriSema to Reclaim Obesity Leadership After 60% Sell-Off2026-05-15 Novo Nordisk rallies on oral Wegovy’s 21.6% weight loss, bests Lilly; CagriSema submitted for US approval. Stock up…
NNovo Nordisk Read More Novo Nordisk Scraps Rare-Disease Factory, Bets on Oral Obesity Pill and CagriSema to Revive Growth2026-05-14 Novo Nordisk pivots from rare diseases to obesity, scrapping a Danish plant and 400 jobs, as it races…
NNovo Nordisk Read More Novo Nordisk’s One-Time Windfall Masks a Deeper Squeeze as Pipeline Bets Take Shape2026-05-08 Novo Nordisk’s Q1 profit surged on a one-off accounting gain, but US sales fell 11% amid pricing pressure.…
NNovo Nordisk Read More Novo Nordisk Bets on AI and Subscriptions to Counter a Steep Slide2026-04-19 Novo Nordisk shares surge as the firm partners with OpenAI to accelerate drug development and expands Wegovy subscription…
NNovo Nordisk Read More Novo Nordisk Bets on AI and New Products to Reverse Steep Share Slide2026-04-16 Novo Nordisk shares rebound on UK Wegovy pen approval. The firm combats a weak outlook with an OpenAI…